Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents
January 9 2024
The efficacy of the BNT162b2 vaccine in paediatrics was assessed by randomised trials before the Omicron variant’s emergence. The long-term durability of vaccine protection in this population during the Omicron period remains limited. The objectives are to assess the effectiveness of BNT162b2 in preventing infection and severe diseases with various strains of the SARS-CoV-2 virus in previously uninfected children and adolescents.
Share
Topics
Mediums
NCD / Risk Groups
